DDInter454 DDInter1763
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Cyclobenzaprine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Cyclobenzaprine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) resembles {v} (Compound) Imipramine
Imipramine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Temsirolimus
Cyclobenzaprine {u} (Compound) resembles {v} (Compound) Naftifine
Naftifine {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Cyclobenzaprine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Cyclobenzaprine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Cyclobenzaprine (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Temsirolimus (Compound)
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Cyclobenzaprine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Cyclobenzaprine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Cyclobenzaprine (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Cyclobenzaprine (Compound) resembles Imipramine (Compound) and Imipramine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Temsirolimus (Compound)
Cyclobenzaprine (Compound) resembles Naftifine (Compound) and Naftifine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Temsirolimus (Compound)
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)